Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors

BACKGROUND: Immune checkpoint inhibitors (ICIs) have become established as a new therapeutic paradigm in various solid cancers. Predictive biomarkers to ICIs have not yet been fully established. Tumor mutational burden (TMB) has been considered as a useful marker to indicate patients who benefit fro...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ther Adv Med Oncol
Main Authors: Kim, Hana, Hong, Jung Yong, Lee, Jeeyun, Park, Se Hoon, Park, Joon Oh, Park, Young Suk, Lim, Ho Yeong, Kang, Won Ki, Kim, Kyoung-Mee, Kim, Seung Tae
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2021
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7917846/
https://ncbi.nlm.nih.gov/pubmed/33717226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835921992992
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki